A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer
Genetic variation at the 19q13.3 KLK locus is linked with prostate cancer susceptibility in men. The non-synonymous KLK3 single nucleotide polymorphism (SNP), rs17632542 (c.536 T > C; Ile163Thr-substitution in PSA) is associated with reduced prostate cancer risk, however, the functional relevance...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Nature Research
2024
|
| _version_ | 1826315237700141056 |
|---|---|
| author | Srinivasan, S Kryza, T Bock, N Tse, BWC Sokolowski, KA Janaththani, P Fernando, A Moya, L Stephens, C Dong, Y Röhl, J Alinezhad, S Vela, I Perry-Keene, JL Buzacott, K Nica, R Gago-Dominguez, M Schleutker, J Maier, C Muir, K Tangen, CM Gronberg, H Pashayan, N Albanes, D Travis, RC Neal, DE |
| author_facet | Srinivasan, S Kryza, T Bock, N Tse, BWC Sokolowski, KA Janaththani, P Fernando, A Moya, L Stephens, C Dong, Y Röhl, J Alinezhad, S Vela, I Perry-Keene, JL Buzacott, K Nica, R Gago-Dominguez, M Schleutker, J Maier, C Muir, K Tangen, CM Gronberg, H Pashayan, N Albanes, D Travis, RC Neal, DE |
| author_sort | Srinivasan, S |
| collection | OXFORD |
| description | Genetic variation at the 19q13.3 KLK locus is linked with prostate cancer susceptibility in men. The non-synonymous KLK3 single nucleotide polymorphism (SNP), rs17632542 (c.536 T > C; Ile163Thr-substitution in PSA) is associated with reduced prostate cancer risk, however, the functional relevance is unknown. Here, we identify that the SNP variant-induced change in PSA biochemical activity mediates prostate cancer pathogenesis. The ‘Thr’ PSA variant leads to small subcutaneous tumours, supporting reduced prostate cancer risk. However, ‘Thr’ PSA also displays higher metastatic potential with pronounced osteolytic activity in an experimental metastasis in-vivo model. Biochemical characterisation of this PSA variant demonstrates markedly reduced proteolytic activity that correlates with differences in in-vivo tumour burden. The SNP is associated with increased risk for aggressive disease and prostate cancer-specific mortality in three independent cohorts, highlighting its critical function in mediating metastasis. Carriers of this SNP allele have reduced serum total PSA and a higher free/total PSA ratio that could contribute to late biopsy decisions and delay in diagnosis. Our results provide a molecular explanation for the prominent 19q13.3 KLK locus, rs17632542 SNP, association with a spectrum of prostate cancer clinical outcomes. |
| first_indexed | 2024-12-09T03:22:14Z |
| format | Journal article |
| id | oxford-uuid:69c54950-9d8c-4e6e-bf9f-c653fb894aa8 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-12-09T03:22:14Z |
| publishDate | 2024 |
| publisher | Nature Research |
| record_format | dspace |
| spelling | oxford-uuid:69c54950-9d8c-4e6e-bf9f-c653fb894aa82024-11-15T20:03:33ZA PSA SNP associates with cellular function and clinical outcome in men with prostate cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:69c54950-9d8c-4e6e-bf9f-c653fb894aa8EnglishJisc Publications RouterNature Research2024Srinivasan, SKryza, TBock, NTse, BWCSokolowski, KAJanaththani, PFernando, AMoya, LStephens, CDong, YRöhl, JAlinezhad, SVela, IPerry-Keene, JLBuzacott, KNica, RGago-Dominguez, MSchleutker, JMaier, CMuir, KTangen, CMGronberg, HPashayan, NAlbanes, DTravis, RCNeal, DEGenetic variation at the 19q13.3 KLK locus is linked with prostate cancer susceptibility in men. The non-synonymous KLK3 single nucleotide polymorphism (SNP), rs17632542 (c.536 T > C; Ile163Thr-substitution in PSA) is associated with reduced prostate cancer risk, however, the functional relevance is unknown. Here, we identify that the SNP variant-induced change in PSA biochemical activity mediates prostate cancer pathogenesis. The ‘Thr’ PSA variant leads to small subcutaneous tumours, supporting reduced prostate cancer risk. However, ‘Thr’ PSA also displays higher metastatic potential with pronounced osteolytic activity in an experimental metastasis in-vivo model. Biochemical characterisation of this PSA variant demonstrates markedly reduced proteolytic activity that correlates with differences in in-vivo tumour burden. The SNP is associated with increased risk for aggressive disease and prostate cancer-specific mortality in three independent cohorts, highlighting its critical function in mediating metastasis. Carriers of this SNP allele have reduced serum total PSA and a higher free/total PSA ratio that could contribute to late biopsy decisions and delay in diagnosis. Our results provide a molecular explanation for the prominent 19q13.3 KLK locus, rs17632542 SNP, association with a spectrum of prostate cancer clinical outcomes. |
| spellingShingle | Srinivasan, S Kryza, T Bock, N Tse, BWC Sokolowski, KA Janaththani, P Fernando, A Moya, L Stephens, C Dong, Y Röhl, J Alinezhad, S Vela, I Perry-Keene, JL Buzacott, K Nica, R Gago-Dominguez, M Schleutker, J Maier, C Muir, K Tangen, CM Gronberg, H Pashayan, N Albanes, D Travis, RC Neal, DE A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer |
| title | A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer |
| title_full | A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer |
| title_fullStr | A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer |
| title_full_unstemmed | A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer |
| title_short | A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer |
| title_sort | psa snp associates with cellular function and clinical outcome in men with prostate cancer |
| work_keys_str_mv | AT srinivasans apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT kryzat apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT bockn apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT tsebwc apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT sokolowskika apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT janaththanip apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT fernandoa apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT moyal apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT stephensc apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT dongy apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT rohlj apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT alinezhads apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT velai apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT perrykeenejl apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT buzacottk apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT nicar apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT gagodominguezm apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT schleutkerj apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT maierc apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT muirk apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT tangencm apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT gronbergh apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT pashayann apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT albanesd apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT travisrc apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT nealde apsasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT srinivasans psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT kryzat psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT bockn psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT tsebwc psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT sokolowskika psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT janaththanip psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT fernandoa psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT moyal psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT stephensc psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT dongy psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT rohlj psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT alinezhads psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT velai psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT perrykeenejl psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT buzacottk psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT nicar psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT gagodominguezm psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT schleutkerj psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT maierc psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT muirk psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT tangencm psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT gronbergh psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT pashayann psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT albanesd psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT travisrc psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer AT nealde psasnpassociateswithcellularfunctionandclinicaloutcomeinmenwithprostatecancer |